Download PDF
Synlett
DOI: 10.1055/a-2331-6463
letter

Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells

Shaonan Wang
1   School of Pharmacy, East China University of Science and Technology, Shanghai, China (Ringgold ID: RIN47860)
,
Min Sun
1   School of Pharmacy, East China University of Science and Technology, Shanghai, China (Ringgold ID: RIN47860)
,
Yajuan Su
1   School of Pharmacy, East China University of Science and Technology, Shanghai, China (Ringgold ID: RIN47860)
,
Zhou Xu
2   Chemistry, Shanghai Institute of Organic Chemistry, Shanghai, China (Ringgold ID: RIN58309)
,
Ang Li 
3   State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry Chinese Academy of Sciences, Shanghai, China (Ringgold ID: RIN58309)
,
Weiwei He
4   School of Pharmacy, East China University of Science and Technology, Shanghai, China (Ringgold ID: RIN47860)
› Author Affiliations
› Further Information
  PDF Download All articles of this category

Deucravacitinib is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2) recently approved by the FDA for the treatment of plaque psoriasis. We discovered that this compound induces proteasomal degradation of YAP1, the downstream effector of the Hippo signaling pathway, in human glioblastoma (GBM) cells (U-87 MG). This degradation is independent of the canonical Hippo pathway, which offers clues to alternative mechanisms for YAP1 regulation.



Publication History

Received: 27 April 2024

Accepted after revision: 22 May 2024

Accepted Manuscript online:
22 May 2024

© . Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany